Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00780494
Recruitment Status : Unknown
Verified September 2012 by Pamela L. Kunz, Stanford University.
Recruitment status was:  Recruiting
First Posted : October 27, 2008
Last Update Posted : September 5, 2012
Genentech, Inc.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : April 2014
  Estimated Study Completion Date : April 2014